AIGH Capital Management LLC Takes $3.98 Million Position in Talphera, Inc. $TLPH

AIGH Capital Management LLC purchased a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,454,545 shares of the company’s stock, valued at approximately $3,979,000. Talphera makes up approximately 1.1% of AIGH Capital Management LLC’s portfolio, making the stock its 24th largest holding. AIGH Capital Management LLC owned approximately 9.56% of Talphera as of its most recent filing with the Securities & Exchange Commission.

Talphera Price Performance

Shares of NASDAQ:TLPH opened at $1.00 on Friday. Talphera, Inc. has a 1 year low of $0.38 and a 1 year high of $1.57. The stock has a market capitalization of $46.61 million, a price-to-earnings ratio of -2.63 and a beta of 0.30. The company’s 50 day simple moving average is $1.17 and its 200 day simple moving average is $0.93.

Talphera (NASDAQ:TLPH) last issued its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. As a group, analysts anticipate that Talphera, Inc. will post -0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.00.

Talphera Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.